Patient Management

2074 soru

Soru 1981Soru →

An occupational health clinic is auditing the medical records of several newly onboarded employees to ensure compliance with age- and risk-appropriate preventive care protocols. Match each employee's clinical profile with their most urgently indicated evidence-based screening or immunization intervention.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 67-year-old male who smoked two packs of cigarettes daily for 20 years before ceasing a decade ago; no prior vascular imaging on record.
A 41-year-old male whose father was diagnosed with a colonic malignancy at age 48.
A 45-year-old female currently receiving a monoclonal antibody targeting TNF-alpha for severe psoriasis.
A 36-year-old female whose last preventive reproductive health visit was five years ago, yielding normal standalone cellular cytology.
A 66-year-old female, strictly up-to-date on age-appropriate malignancy surveillance, presenting for her initial senior wellness assessment.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The 67-year-old former smoker matches with lung and AAA screening; the 41-year-old with a family history of early CRC matches with optical colonoscopy; the 45-year-old on biologic therapy matches with non-live immunizations; the 36-year-old overdue for a Pap smear matches with cervical surveillance; and the healthy 66-year-old female matches with bone densitometry.
Each patient's clinical profile aligns precisely with current USPSTF and ACIP guidelines. The 67-year-old former heavy smoker requires dual screening for lung cancer and an abdominal aortic aneurysm. The 41-year-old with a strong family history requires high-risk optical colonoscopy. The immunosuppressed 45-year-old must receive non-live pneumococcal and zoster vaccines. The 36-year-old is overdue for cervical surveillance following a 5-year gap since a standalone cytology. The 66-year-old female meets the age threshold for baseline osteoporosis screening.

Adım Adım Çözüm

1
Analyze the 67-year-old male's smoking history and demographic profile.
Patient has a 40 pack-year smoking history, quit 10 years ago, and is a male over 65.
Determines eligibility for both annual low-dose chest CT (age 50-80, 20+ pack-years, quit <15 years ago) and one-time AAA ultrasound (men 65-75 with any smoking history).
2
Assess the 41-year-old male's familial risk for colorectal cancer.
Identified a first-degree relative diagnosed at age 48.
Shifts management to high-risk screening, requiring colonoscopy at age 40 (or 10 years prior to the relative's diagnosis) and repeating every 5 years.
3
Evaluate the immunization needs of the 45-year-old female on a TNF-alpha inhibitor.
Patient is actively immunosuppressed due to targeted biologic therapy.
Indicates the need for pneumococcal vaccination and the recombinant zoster vaccine (>19 years old for immunocompromised), while mandating the avoidance of live-attenuated vaccines.
4
Review the cervical screening timeline for the 36-year-old female.
The last documented screening was cytology alone 5 years ago.
Identifies the patient as overdue, as cytology alone requires a 3-year interval. She now requires standard screening (hrHPV, cytology, or co-testing).
5
Determine the standard age-based screening for the healthy 66-year-old female.
Patient is female and >65 years old with no prior fracture history.
Triggers the USPSTF recommendation for baseline osteoporosis screening via bone densitometry.

Anahtar Kavram

Evidence-based preventive care and screening guidelines tailored to patient age, sex, familial risk factors, and iatrogenic immunosuppression.
Soru 1982Soru →

Paramedics bring a 45-year-old female to the emergency department due to worsening dyspnea, blurred vision, and an intense headache over the past 12 hours. The patient was diagnosed with diffuse cutaneous systemic sclerosis four years ago and takes mycophenolate mofetil. Vital signs show a temperature of 37.1°C (98.8°F), blood pressure of 228/118 mm Hg, pulse of 106/min, and respiratory rate of 24/min. Pulse oximetry is 94% on room air. Physical examination is notable for diffuse skin thickening sparing the clavicles and bilateral basilar crackles.

Laboratory studies reveal:
Hemoglobin: 8.9 g/dL
Platelets: 78,000/mm³
Creatinine: 3.6 mg/dL (baseline: 0.8 mg/dL)
Lactate dehydrogenase: 940 U/L
Urinalysis: 2+ protein, no red blood cell casts

A peripheral blood smear demonstrates fragmented red blood cells. Which of the following is the most appropriate initial pharmacologic intervention?

Cevabı ve açıklamayı göster

Cevap: Oral captopril

Cevap

Oral captopril
The correct answer is oral captopril. This patient is presenting with scleroderma renal crisis (SRC), characterized by malignant hypertension, acute kidney injury, and microangiopathic hemolytic anemia (evidenced by schistocytes, thrombocytopenia, and elevated LDH) in the setting of systemic sclerosis. The pathophysiology involves intimal proliferation of the renal arcuate and interlobular arteries, leading to severe renal ischemia and massive activation of the renin-angiotensin-aldosterone system (RAAS). ACE inhibitors are the cornerstone of treatment and should be initiated immediately to reverse the RAAS activation. Captopril is the preferred agent because its short half-life allows for rapid and safe dose titration. Unlike most cases of acute kidney injury, where ACE inhibitors are typically withheld or discontinued, SRC uniquely requires their immediate administration to preserve long-term renal function and reduce mortality.

Adım Adım Çözüm

1
Identify the primary clinical syndrome from the presentation.
The patient has Scleroderma Renal Crisis (SRC), defined by malignant hypertension, acute kidney injury, and microangiopathic hemolytic anemia in a patient with systemic sclerosis.
Synthesizing the underlying rheumatologic diagnosis with the acute hypertensive and hematologic findings is required to identify the specific crisis.
2
Determine the underlying pathophysiology driving the crisis.
SRC is driven by intense renal vascular ischemia leading to massive activation of the renin-angiotensin-aldosterone system (RAAS).
Understanding the RAAS-driven mechanism distinguishes SRC from other generic hypertensive emergencies.
3
Select the appropriate targeted pharmacologic intervention.
A short-acting ACE inhibitor, such as oral captopril, must be initiated immediately.
ACE inhibitors are uniquely indicated in SRC to break the cycle of renin release, and they are mandatory even when acute kidney injury is present.

Anahtar Kavram

Scleroderma Renal Crisis presents with severe hypertension, acute kidney injury, and microangiopathic hemolytic anemia. It must be treated immediately with short-acting ACE inhibitors (e.g., captopril), overriding the usual contraindication of using ACE inhibitors in acute kidney injury.
Tahmini Süre:1m 30s
Soru 1983Soru →

A 72-year-old man develops massive abdominal distension on postoperative day 4 following a right total knee arthroplasty. He is currently receiving intravenous hydromorphone for pain control. He reports nausea and diffuse abdominal discomfort but denies severe sharp pain or vomiting. He is still passing flatus. His temperature is 37.2∘C37.2^{\circ}\text{C} (99.0∘F99.0^{\circ}\text{F}), blood pressure is 130/80 mmHg130/80\text{ mmHg}, and heart rate is 88/min88/\text{min}. On physical examination, the abdomen is markedly distended and tympanitic, with high-pitched bowel sounds. There is no involuntary guarding or rebound tenderness. Laboratory studies show a serum sodium of 138 mEq/L138\text{ mEq/L}, potassium of 4.0 mEq/L4.0\text{ mEq/L}, and calcium of 9.2 mg/dL9.2\text{ mg/dL}. A CT scan of the abdomen and pelvis with intravenous contrast reveals massive dilation of the cecum, ascending colon, and transverse colon with a maximum cecal diameter of 11.0 cm11.0\text{ cm}. There is no mechanical transition point, free intraperitoneal air, or bowel wall pneumatosis. Arrange the following procedural and management steps in the correct sequential order for this patient according to standard guidelines, assuming each preceding intervention fails to resolve the condition.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence of management for acute colonic pseudo-obstruction begins with conservative therapy (discontinuing opioids/bowel rest), progresses to pharmacologic therapy (neostigmine), followed by endoscopic decompression, and concludes with surgical intervention as a last resort.
Acute colonic pseudo-obstruction (Ogilvie syndrome) involves massive dilation of the colon in the absence of mechanical obstruction. The standard algorithm dictates an escalating scale of interventions. First, conservative management must be instituted by discontinuing offending agents (e.g., narcotics, anticholinergics), placing a nasogastric tube, and correcting electrolyte derangements. If this fails within 24-48 hours and the cecum reaches a critical diameter (typically >10 cm>10\text{ cm}), pharmacologic decompression with neostigmine is the next step. If the patient has a contraindication to neostigmine or the medication fails, endoscopic colonic decompression is performed. Finally, if all medical and endoscopic measures fail, or if there is evidence of peritonitis or perforation, surgical intervention (such as a tube cecostomy or segmental resection) is required.

Adım Adım Çözüm

1
Analyze the clinical presentation and diagnostic imaging.
The patient has massive colonic dilation without a mechanical transition point, normal electrolytes, and a history of recent surgery with opioid use. This confirms the diagnosis of acute colonic pseudo-obstruction (Ogilvie syndrome).
Establishing the correct diagnosis rules out mechanical obstruction, which would mandate immediate surgical or endoscopic intervention rather than medical management.
2
Evaluate the patient for signs of impending complication.
The patient is hemodynamically stable, lacks peritoneal signs, and the CT scan shows no free air or bowel wall ischemia. The cecum is dilated to 11.0 cm11.0\text{ cm}, which warrants close monitoring and step-wise intervention.
The absence of peritonitis or perforation dictates that the management approach should begin with the least invasive options before escalating.
3
Sequence the interventions based on ascending invasiveness and risk.
The sequence is: 1) Conservative care, 2) Pharmacologic therapy, 3) Endoscopic procedures, 4) Surgical procedures.
Standard surgical guidelines dictate minimizing iatrogenic harm by exhausting medical management before pursuing invasive procedures with higher morbidity.

Anahtar Kavram

The step-wise procedural management algorithm for acute colonic pseudo-obstruction (Ogilvie syndrome).
Soru 1984Soru →

A 67-year-old man comes to the clinic to establish care after moving to a new city. He reports feeling well and has no current symptoms. His past medical history includes essential hypertension, which is well-controlled with lisinopril. He had an appendectomy at age 20. Social history is notable for smoking 1 pack of cigarettes daily from age 18 to age 25, after which he completely quit. He drinks 1 to 2 glasses of wine on the weekends.

His last colonoscopy was 3 years ago and was completely normal. A fasting lipid panel and hemoglobin A1c were checked 2 months ago and were within normal limits. A one-time hepatitis C virus antibody test was negative 5 years ago. At age 65, he received the 20-valent pneumococcal conjugate vaccine (PCV20) and completed the recombinant zoster vaccine series. He received a Tetanus, Diphtheria, Pertussis (Tdap) booster 4 years ago and the seasonal influenza vaccine last week.

Vital signs and physical examination are unremarkable.

Which of the following is the most appropriate next step in this patient's preventive care?

Cevabı ve açıklamayı göster

Cevap: One-time abdominal ultrasonography

Cevap

One-time abdominal ultrasonography
The correct answer is one-time abdominal ultrasonography. The United States Preventive Services Task Force (USPSTF) recommends a one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked. 'Ever smoked' is strictly defined as having smoked at least 100 cigarettes in a lifetime. This patient smoked 1 pack of cigarettes daily for 7 years, significantly exceeding the 100-cigarette threshold, and falls within the target age range. Therefore, he definitively requires AAA screening.

Adım Adım Çözüm

1
Evaluate the patient's age and demographic risk factors.
The patient is a 67-year-old man.
Age and biological sex dictate specific USPSTF screening pathways, particularly for vascular and oncologic diseases.
2
Analyze the patient's social history for substance exposures.
The patient has a smoking history of 1 pack per day for 7 years and quit 42 years ago. This totals more than 100 cigarettes in his lifetime.
Smoking history is a critical criterion for determining the necessity of abdominal aortic aneurysm and lung cancer screenings.
3
Synthesize demographics and exposures with current preventive guidelines.
As a man aged 65 to 75 who has 'ever smoked', he meets the precise criteria for a one-time abdominal aortic aneurysm screening.
The USPSTF Grade B recommendation mandates a one-time ultrasound for AAA in this specific demographic.

Anahtar Kavram

The USPSTF recommends a one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked, which is strictly defined as having smoked 100 or more cigarettes in their lifetime.
Soru 1985Soru →

A 2828-year-old woman is evaluated in the psychiatric clinic for an acute manic episode characterized by a decreased need for sleep, grandiosity, and hyperverbosity. She is subsequently diagnosed with bipolar I disorder. Following a comprehensive discussion regarding mood stabilization, the physician decides to initiate therapy with lithium carbonate. In addition to monitoring serum medication concentrations, which of the following laboratory parameters must be evaluated at baseline and periodically monitored during long-term maintenance therapy with this agent? (Select exactly 33 options)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Serum calcium; Serum creatinine; Thyroid-stimulating hormone

Cevap

The required baseline and ongoing laboratory parameters for lithium therapy are serum calcium, serum creatinine, and thyroid-stimulating hormone.
The correct options identify the three main organ systems adversely affected by chronic lithium therapy: the parathyroid glands, the kidneys, and the thyroid gland. Lithium alters the calcium-sensing receptor threshold in the parathyroid gland, necessitating serum calcium monitoring to detect hyperparathyroidism. It is exclusively eliminated by the kidneys and can cause acute kidney injury, nephrogenic diabetes insipidus, and chronic tubulointerstitial nephropathy, requiring routine serum creatinine evaluation. Finally, it inhibits thyroid hormone synthesis, frequently leading to clinical hypothyroidism, which makes regular thyroid-stimulating hormone checks essential.

Adım Adım Çözüm

1
Identify the prescribed medication and its organ-specific adverse effect profile.
The patient is starting lithium carbonate, which is known to affect the kidneys, thyroid gland, and parathyroid glands.
Pharmacologic monitoring is directly dictated by a drug's metabolism, excretion, and known end-organ toxicities.
2
Select the appropriate laboratory tests corresponding to lithium's toxicity profile.
Serum creatinine (for renal function), thyroid-stimulating hormone (for thyroid function), and serum calcium (for parathyroid function) are required.
These tests detect the development of chronic tubulointerstitial nephropathy, hypothyroidism, and hyperparathyroidism, respectively.
3
Differentiate lithium's monitoring requirements from those of other psychiatric medications.
Hepatic transaminases and absolute neutrophil count are excluded, as lithium does not cause hepatotoxicity or agranulocytosis.
Avoiding unnecessary testing prevents diagnostic confusion and adheres to standard-of-care guidelines.

Anahtar Kavram

Patients initiated on lithium therapy require baseline and periodic monitoring of serum creatinine (due to the risk of tubulointerstitial nephropathy), thyroid-stimulating hormone (due to the risk of hypothyroidism), and serum calcium (due to the risk of hyperparathyroidism).
Soru 1986Soru →

A physician evaluates a 2828-year-old woman during her first prenatal visit at 88 weeks of gestation. She has a medical history of primary hypothyroidism due to Hashimoto thyroiditis and has been well-controlled on a stable daily dose of 100 \mug100 \text{ \mu g} of levothyroxine for the past two years. She reports mild fatigue but denies palpitations, heat intolerance, or vaginal bleeding. Her vital signs are within normal limits. Physical examination is unremarkable, with a normal-sized thyroid gland and no palpable nodules. Laboratory studies obtained today reveal a thyroid-stimulating hormone (TSH) level of 4.8 mIU/L4.8 \text{ mIU/L} (reference range for the first trimester: 0.10.1 to 2.5 mIU/L2.5 \text{ mIU/L}) and a free thyroxine (T4) level at the lower limit of normal. Which of the following is the most appropriate next step in the management of this patient's thyroid disease?

Cevabı ve açıklamayı göster

Cevap: Increase the levothyroxine dose by approximately 30%30\% and recheck serum TSH in 44 weeks

Cevap

Increase the levothyroxine dose by approximately 30% and recheck serum TSH in 4 weeks.
The correct answer addresses the physiological changes of early pregnancy. Increased circulating estrogen stimulates the hepatic synthesis of thyroxine-binding globulin (TBG). This excess TBG binds free T4, transiently lowering active hormone levels and triggering an increase in TSH. In a healthy individual, the thyroid gland responds by increasing T4 production. However, a patient with Hashimoto thyroiditis cannot mount this endogenous response. Consequently, as soon as pregnancy is confirmed, the exogenous levothyroxine dose should be preemptively increased by approximately 30% (often achieved by advising the patient to take two additional doses per week). The TSH must then be rechecked in 4 weeks to ensure it falls within the trimester-specific target range (typically 0.1 to 2.5 mIU/L for the first trimester) to prevent adverse outcomes such as spontaneous abortion, preterm birth, and impaired fetal neurocognitive development.

Adım Adım Çözüm

1
Identify the patient's condition and physiological state.
The patient is a pregnant female at 8 weeks gestation with a history of Hashimoto thyroiditis, currently taking levothyroxine.
Pregnancy significantly alters thyroid hormone pharmacokinetics and physiological requirements.
2
Interpret the laboratory results within the correct clinical context.
The TSH of 4.8 mIU/L is elevated above the strict first-trimester target of less than 2.5 mIU/L.
Pregnancy-specific reference ranges must be used to ensure adequate maternal T4 delivery to the fetus.
3
Determine the physiological mechanism driving the lab abnormality.
Increased maternal estrogen stimulates thyroxine-binding globulin (TBG) production, which binds more free T4 and increases the overall thyroid hormone demand.
Understanding the mechanism explains why the patient's baseline dose is suddenly inadequate.
4
Select the appropriate management step.
The exogenous levothyroxine dose must be empirically increased by approximately 30% with a TSH re-evaluation in 4 weeks.
Because the patient's diseased thyroid gland cannot autonomously increase production to meet pregnancy demands, the clinician must proactively increase the synthetic hormone dose to prevent fetal complications.

Anahtar Kavram

Due to increased thyroxine-binding globulin (TBG) and the metabolic demands of pregnancy, patients with preexisting primary hypothyroidism require an immediate dose increase in their levothyroxine (typically by 30%) as soon as pregnancy is confirmed, followed by serial TSH monitoring.
Soru 1987Soru →

Following a recent change in her employment benefits, a 50-year-old female schedules an appointment for a comprehensive health evaluation. She mentions that her last medical visit was over a decade ago. She reports feeling well and has no acute or chronic complaints. Her past medical history is notable only for two uncomplicated vaginal deliveries in her twenties. Family history is unremarkable for early-onset malignancies or cardiovascular diseases. She has never smoked, does not consume alcohol, and exercises occasionally. Her blood pressure is 128/78 mmHg, heart rate is 76/min, and body mass index is 33 kg/m^2. Physical examination, including a clinical breast examination and pelvic examination, reveals no abnormalities. Which of the following screening interventions are indicated for this patient at this time? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Fecal immunochemical testing; Hemoglobin A1c measurement

Cevap

The indicated screening interventions for this patient are fecal immunochemical testing and hemoglobin A1c measurement.
Fecal immunochemical testing and hemoglobin A1c measurement are both strongly indicated for this patient. Current United States Preventive Services Task Force (USPSTF) guidelines recommend colorectal cancer screening for all average-risk adults beginning at age 45; therefore, offering a fecal immunochemical test (or another modality such as screening colonoscopy) is appropriate for this 50-year-old patient. Additionally, the USPSTF recommends screening for prediabetes and type 2 diabetes in nonpregnant adults aged 35 to 70 years who are overweight or obese. Given the patient's body mass index of 33 kg/m^2, measuring her hemoglobin A1c (or fasting plasma glucose) is a necessary next step in her preventive care.

Adım Adım Çözüm

1
Analyze the patient's demographic and biometric profile.
The patient is a 50-year-old female with a body mass index of 33 kg/m^2 (obesity) and no history of smoking.
Preventive screening guidelines are highly dependent on age, biological sex, body mass index, and specific lifestyle risk factors.
2
Evaluate the need for cancer screenings.
Colorectal cancer screening is indicated due to her age (>45). Lung cancer screening is not indicated (no smoking history). Ovarian cancer screening is not indicated for average-risk women.
Applying current evidence-based guidelines ensures appropriate resource utilization and minimizes patient harm from false positives.
3
Evaluate the need for metabolic and musculoskeletal screenings.
Screening for type 2 diabetes is indicated due to her age and elevated body mass index. Bone density screening is not indicated as she is under 65 without specific high-risk factors.
Targeted screening catches asymptomatic metabolic conditions early while avoiding unnecessary testing for conditions with low pretest probability.

Anahtar Kavram

Age- and risk-factor-appropriate preventive screening
Soru 1988Soru →

A 6868-year-old man is evaluated in the intensive care unit for worsening lethargy and confusion. He was admitted 55 days ago for severe community-acquired pneumonia and subsequently developed acute kidney injury. His past medical history is significant for hypertension, type 2 diabetes mellitus, and a focal seizure disorder for which he takes a stable dose of phenytoin. Currently, his temperature is 37.2∘37.2^\circ C (99.0∘99.0^\circ F), blood pressure is 118/74118/74 mmHg, and pulse is 8888/min. Physical examination reveals prominent horizontal nystagmus, slurred speech, and bilateral intention tremor. Laboratory studies show:

Blood urea nitrogen: 6868 mg/dL
Serum creatinine: 3.83.8 mg/dL
Serum albumin: 2.22.2 g/dL
Total serum phenytoin: 1212 mg/L (therapeutic range: 10−2010-20 mg/L)

Which of the following is the most appropriate next step in the evaluation of this patient?

Cevabı ve açıklamayı göster

Cevap: Measure the unbound serum phenytoin concentration

Cevap

Measure the unbound serum phenytoin concentration
The correct action is to measure the unbound (free) serum phenytoin concentration. Phenytoin is approximately 90%90\% bound to plasma proteins, primarily albumin. In patients with severe hypoalbuminemia or uremia (where accumulated endogenous toxins competitively inhibit drug binding), the fraction of unbound, pharmacologically active phenytoin increases significantly. Because the standard serum phenytoin assay measures total (both bound and unbound) drug, the total level may appear to be within the normal therapeutic range (10−2010-20 mg/L) even when the free fraction is dangerously elevated. This patient demonstrates classic signs of phenytoin toxicity, including horizontal nystagmus, ataxia, and lethargy. To accurately evaluate and manage this suspected toxicity, the unbound phenytoin concentration (normal range 1−21-2 mg/L) must be measured.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation.
The patient exhibits lethargy, horizontal nystagmus, slurred speech, and intention tremor.
These findings are classic clinical manifestations of cerebellar and vestibular dysfunction associated with phenytoin toxicity.
2
Correlate the physical findings with the laboratory results.
The total serum phenytoin level is 1212 mg/L, which is technically within the normal therapeutic range of 10−2010-20 mg/L. However, the patient has severe hypoalbuminemia (2.22.2 g/dL) and uremia (BUN 6868 mg/dL).
Phenytoin is a highly protein-bound drug. Hypoalbuminemia reduces the total number of binding sites, while uremic toxins competitively displace phenytoin from albumin.
3
Determine the impact of the metabolic derangements on drug pharmacokinetics.
The decreased protein binding leads to a significantly increased fraction of free (unbound), pharmacologically active phenytoin.
The standard 'total' phenytoin assay measures both bound and unbound drug. In this altered state, the total level appears falsely reassuring, while the free level is well into the toxic range.
4
Select the most appropriate monitoring intervention.
The correct action is to measure the unbound (free) serum phenytoin concentration.
This confirms the suspected toxicity and guides subsequent dosage adjustments or the decision to temporarily withhold the drug.

Anahtar Kavram

Therapeutic drug monitoring of highly protein-bound medications in states of altered protein binding.
Tahmini Süre:1m 30s
Soru 1989Soru →

A 54-year-old woman is evaluated in the hospital on the second day of her admission for a mechanical small bowel obstruction. She originally presented with cramping abdominal pain, bilious vomiting, and failure to pass flatus. Her surgical history is notable for a total abdominal hysterectomy performed 55 years ago. Initial management included bowel rest, intravenous fluid resuscitation, and nasogastric tube decompression. Over the last 44 hours, her abdominal pain has transitioned from intermittent cramps to a severe, constant ache. Her temperature is 38.6∘C38.6^\circ\text{C} (101.5∘F101.5^\circ\text{F}), blood pressure is 98/60 mm Hg98/60\text{ mm Hg}, and pulse is 115/min115/\text{min}. Physical examination now reveals a rigid, distended abdomen with significant rebound tenderness and involuntary guarding in all four quadrants. Laboratory studies obtained 30 minutes30\text{ minutes} ago show a leukocyte count of 16,500/mm316,500/\text{mm}^3 and a serum lactate level of 4.2 mmol/L4.2\text{ mmol/L}. Which of the following is the most appropriate next step in the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Exploratory laparotomy

Cevap

Exploratory laparotomy
The correct answer is to proceed immediately to the operating room. This patient's clinical presentation has evolved from a simple mechanical small bowel obstruction (managed initially with bowel rest and nasogastric decompression) to a complicated, strangulated obstruction. The transition to severe, constant pain, along with the development of fever, tachycardia, leukocytosis, elevated serum lactate, and generalized peritonitis (rebound tenderness, guarding, rigidity), strongly indicates bowel ischemia and possible perforation. The standard of care for a patient with signs of peritonitis and bowel ischemia is immediate surgical intervention via exploratory laparotomy to resect the necrotic bowel and address the source of the obstruction. Delaying surgery for further diagnostic testing or prolonged medical management significantly increases mortality.

Adım Adım Çözüm

1
Evaluate the patient's evolving clinical symptoms and vital signs.
The patient demonstrates new-onset fever, tachycardia, hypotension, and a transition from colicky to severe, constant abdominal pain.
To identify clinical deterioration that suggests a shift from simple mechanical obstruction to a complicated state.
2
Correlate the physical examination findings with recent laboratory results.
A rigid, distended abdomen with generalized rebound tenderness, combined with significant leukocytosis and elevated serum lactate, indicates generalized peritonitis and bowel ischemia.
To differentiate between a simple mechanical obstruction that can be managed conservatively and a strangulated obstruction that requires escalation of care.
3
Determine the definitive procedural intervention based on the diagnosis of a strangulated small bowel obstruction.
Immediate exploratory laparotomy is required.
When a patient exhibits clear signs of peritonitis and ischemic bowel, conservative management must be abandoned in favor of prompt surgical resection of the necrotic tissue to prevent overwhelming sepsis and death.

Anahtar Kavram

Indications for emergent exploratory laparotomy in patients with complicated small bowel obstruction
Soru 1990Soru →

A 62-year-old female is hospitalized for an exacerbation of chronic obstructive pulmonary disease. She has been receiving subcutaneous unfractionated heparin for deep vein thrombosis prophylaxis. On hospital day 6, her right leg becomes acutely swollen and painful. Venous duplex ultrasonography reveals a new popliteal vein thrombosis. Her platelet count, which was 240,000/mm3240,000/\text{mm}^3 on admission, is now 95,000/mm395,000/\text{mm}^3. The clinical team suspects heparin-induced thrombocytopenia (HIT).

Arrange the following pharmacologic management steps in the strict chronological sequence required to safely treat this patient and transition her to long-term anticoagulation.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence is to first discontinue unfractionated heparin, immediately initiate intravenous argatroban, delay the initiation of oral warfarin until platelets recover, and finally discontinue argatroban only after an adequate overlap period with a therapeutic INR.
The precise chronological management of HIT requires stopping heparin first to remove the trigger. Second, because of the massive thrombotic risk, an alternative parenteral agent (argatroban) must be started. Third, transition to warfarin must be delayed until platelet recovery (≥150,000/mm3\geq 150,000/\text{mm}^3) to prevent venous limb gangrene. Finally, the parenteral agent is stopped only after a 5-day overlap and a stable, therapeutic INR are confirmed.

Adım Adım Çözüm

1
Halt the offending agent.
Unfractionated heparin is discontinued immediately.
Continuing heparin fuels the production of immunogenic PF4-heparin complexes, perpetuating platelet activation and thrombosis.
2
Provide immediate alternative anticoagulation.
A direct thrombin inhibitor (argatroban) is initiated.
HIT is a highly hypercoagulable state. Since the patient has an acute deep vein thrombosis, therapeutic anticoagulation must be established urgently with a safe alternative.
3
Transition to oral maintenance therapy.
Warfarin is initiated strictly after the platelet count recovers to ≥150,000/mm3\geq 150,000/\text{mm}^3.
Premature warfarin initiation rapidly depletes Protein C (which has a short half-life), severely exacerbating the hypercoagulable state and risking venous limb gangrene.
4
Complete the transition.
Argatroban is discontinued.
Ensures warfarin has achieved its full therapeutic effect. The standard requirement is overlapping both drugs for ≥5\geq 5 days AND a therapeutic INR for at least 24 hours.

Anahtar Kavram

The pharmacologic transition sequence in Heparin-Induced Thrombocytopenia (HIT): Immediate cessation of heparin, prompt initiation of a direct thrombin inhibitor, and delayed initiation of warfarin until platelet recovery.
Tahmini Süre:1m 30s
Soru 1991Soru →

An internal medicine resident is outlining the longitudinal care plan for a 5555-year-old patient who was recently diagnosed with severe non-ischemic cardiomyopathy. The patient's initial echocardiogram revealed a left ventricular ejection fraction of 22%22\%. Prior to hospital discharge yesterday, the patient was successfully stabilized and transitioned to oral quadruple guideline-directed medical therapy, including an angiotensin receptor-neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter-22 inhibitor. Arrange the following outpatient monitoring and treatment evaluation steps in the most appropriate chronological order.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence is: evaluate serum potassium/renal function →\rightarrow up-titrate pharmacotherapies →\rightarrow perform follow-up echocardiogram →\rightarrow assess eligibility for an implantable cardioverter-defibrillator.
The correct sequence follows guideline-directed protocols for newly diagnosed heart failure with reduced ejection fraction. Immediate priority (11-22 weeks) is monitoring for dangerous laboratory shifts caused by new medications. Once safety is established, the next priority is achieving target doses. Only after a sustained period (33-66 months) on target doses can the true efficacy be evaluated via repeat echocardiography. Finally, persistent severe dysfunction post-optimization triggers evaluation for device therapy.

Adım Adım Çözüm

1
Identify the immediate post-discharge monitoring requirement.
Checking a basic metabolic panel for potassium and creatinine within 11 to 22 weeks.
Initiation of neurohormonal blockade, specifically mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors, carries a high early risk of life-threatening hyperkalemia and renal dysfunction.
2
Determine the subsequent phase of outpatient medical management.
Dose titration of medications every 22 to 44 weeks.
The morbidity and mortality benefits of guideline-directed medical therapy are dose-dependent, necessitating a stepwise up-titration over several weeks to reach established target doses.
3
Establish the timeline for evaluating the ultimate efficacy of the medical treatment.
Repeating a transthoracic echocardiogram in 33 to 66 months.
Left ventricular reverse remodeling takes considerable time. Early imaging may falsely suggest failure of therapy; patients must receive a full trial of optimized target-dose therapy before reassessment.
4
Identify the final therapeutic intervention based on lack of sufficient myocardial recovery.
Evaluation for an implantable cardioverter-defibrillator.
Primary prevention devices are strictly indicated only when the ejection fraction remains ≤35%\leq 35\% after a complete 33 to 66 month trial of optimal medical therapy.

Anahtar Kavram

The longitudinal evaluation of heart failure requires early laboratory monitoring for adverse effects (11-22 weeks), subsequent up-titration of medications to target doses, delayed reassessment of cardiac function (33-66 months), and finally consideration of device therapy if recovery is insufficient.
Soru 1992Soru →

A 62-year-old woman presents to her primary care physician for a routine health maintenance evaluation. She has no acute medical complaints today and feels well. Her past medical history is notable for hypertension, which is well-controlled on amlodipine, and obesity. Her body mass index is 32 kg/m². Social history reveals she is a former smoker who smoked 1 pack of cigarettes daily for 30 years before quitting 16 years ago. She currently drinks one glass of wine occasionally.

Review of her preventive screening records shows she underwent a screening colonoscopy at age 55 that revealed no polyps or abnormalities. She had a normal screening mammogram 6 months ago. Her last Pap smear with high-risk human papillomavirus (HPV) co-testing was performed at age 59 and was negative for both. Her hepatitis C antibody test was negative 3 years ago. Regarding immunizations, she received an annual influenza vaccine last month and a Tdap booster 4 years ago. She has no history of receiving the recombinant zoster vaccine or any pneumococcal vaccines.

Which of the following is the most appropriate next step in preventive care for this patient?

Cevabı ve açıklamayı göster

Cevap: Administer recombinant zoster vaccine

Cevap

Administer recombinant zoster vaccine
The recombinant zoster vaccine is recommended by the Advisory Committee on Immunization Practices (ACIP) as a two-dose series for all immunocompetent adults aged 50 years and older to prevent herpes zoster (shingles) and its complications, such as postherpetic neuralgia. Since this 62-year-old patient has no history of receiving it, administering the first dose is an essential and strongly indicated step in her preventive care today.

Adım Adım Çözüm

1
Analyze the patient's demographic and social risk factors
The patient is a 62-year-old female, obese, with a 30 pack-year smoking history who quit 16 years ago.
Age and smoking history strictly dictate the timing of specific cancer screenings and immunizations.
2
Evaluate prior screening intervals for cancer and chronic disease
Colonoscopy at 55 was normal (due in 10 years at age 65). Mammogram at 61.5 is normal (due biennially or annually). Pap/HPV co-test at 59 is negative (due in 5 years at age 64).
Determining current screening needs requires calculating the next due date based on the results of the most recent tests.
3
Apply lung cancer screening criteria
Although she has a >= 20 pack-year history, she quit 16 years ago. USPSTF guidelines state screening should stop once a person has not smoked for 15 years.
Lung cancer screening with low-dose CT is heavily age- and cessation-time dependent.
4
Evaluate immunization status according to ACIP schedules
She lacks the recombinant zoster vaccine, which is universally recommended starting at age 50. She does not meet the criteria for early pneumococcal vaccination.
Identifying missing indicated vaccines is a core component of adult preventive health maintenance.

Anahtar Kavram

Evidence-based preventive screening and immunization intervals for older adults
Soru 1993Soru →

A 3434-year-old woman comes to the clinic for an acute visit. Four weeks ago, she was diagnosed with Graves disease and was started on methimazole and propranolol. She reports that her palpitations and hand tremors have significantly improved. However, yesterday she developed a mild sore throat and a subjective fever.

Her temperature is 37.2∘C37.2^\circ\text{C} (99.0∘F99.0^\circ\text{F}), blood pressure is 118/76 mmHg118/76\text{ mmHg}, pulse is 82/min82/\text{min}, and respirations are 14/min14/\text{min}. Physical examination shows mild pharyngeal erythema without tonsillar exudates, palatal petechiae, or cervical lymphadenopathy. Her thyroid gland is diffusely enlarged, smooth, and non-tender.

Laboratory evaluation reveals the following:

Laboratory ParameterResultReference Range
Leukocyte count3,400/μL3,400/\mu\text{L}4,000−11,000/μL4,000 - 11,000/\mu\text{L}
Absolute neutrophil count1,600/μL1,600/\mu\text{L}1,500−8,000/μL1,500 - 8,000/\mu\text{L}
Hemoglobin13.2 g/dL13.2\text{ g/dL}12.0−15.5 g/dL12.0 - 15.5\text{ g/dL}
Platelet count240,000/μL240,000/\mu\text{L}150,000−400,000/μL150,000 - 400,000/\mu\text{L}
Thyroid-stimulating hormone (TSH)<0.01 μU/mL<0.01\text{ }\mu\text{U/mL}0.4−4.2 μU/mL0.4 - 4.2\text{ }\mu\text{U/mL}
Free thyroxine (T4)1.9 ng/dL1.9\text{ ng/dL}0.8−1.8 ng/dL0.8 - 1.8\text{ ng/dL}

Which of the following is the most appropriate next step in the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Continue methimazole and provide supportive care

Cevap

Continue methimazole and provide supportive care
The correct action is to continue methimazole and provide supportive care. Methimazole and propylthiouracil (thionamides) carry a rare but life-threatening risk of agranulocytosis (ANC <500/μL< 500/\mu\text{L}), typically occurring within the first 90 days of therapy. Because the onset is idiosyncratic and sudden, routine CBC monitoring is not recommended. Instead, patients are instructed to seek immediate evaluation and obtain a CBC if they develop a fever or sore throat. In this patient, the total white blood cell count is mildly low (3,400/μL3,400/\mu\text{L}), but her absolute neutrophil count is normal (1,600/μL1,600/\mu\text{L}). This rules out agranulocytosis. Mild transient leukopenia with a preserved ANC is observed in up to 12% of patients with untreated or treated Graves disease. It is a benign condition (often due to the underlying autoimmune process itself) and is not a precursor to agranulocytosis. Therefore, her thionamide therapy should not be interrupted, and she should simply receive supportive care for her uncomplicated viral pharyngitis.

Adım Adım Çözüm

1
Evaluate the patient's clinical presentation and the indication for laboratory testing.
The patient, who is on methimazole, presents with a sore throat and fever, appropriately prompting a complete blood count to rule out thionamide-induced agranulocytosis.
Agranulocytosis is a rare but life-threatening complication of thionamides that typically presents with sudden infectious symptoms within the first 90 days of therapy.
2
Interpret the laboratory findings with a specific focus on the leukocyte differential.
The total leukocyte count is mildly decreased (3,400/μL3,400/\mu\text{L}), but the absolute neutrophil count (ANC) is well within the normal range (1,600/μL1,600/\mu\text{L}).
Agranulocytosis is strictly defined as an ANC <500/μL< 500/\mu\text{L}. The presence of a normal ANC definitively rules out this condition.
3
Determine the appropriate treatment intervention based on the established diagnosis.
The patient's mild leukopenia is benign, and the methimazole should be continued without interruption while providing symptomatic relief for the viral upper respiratory infection.
Mild, transient leukopenia (WBC <4,000/μL< 4,000/\mu\text{L} with preserved ANC) is seen in up to 12% of patients with Graves disease due to autoimmune margination or a mild drug effect; it does not progress to agranulocytosis and does not require drug cessation.

Anahtar Kavram

Patients taking thionamides who develop infectious symptoms must be evaluated with a CBC; if the absolute neutrophil count (ANC) is normal (≥1,500/μL\geq 1,500/\mu\text{L}), the drug should be continued, as mild leukopenia is a common, benign feature of Graves disease.
Tahmini Süre:1m 30s
Soru 1994Soru →

A 74-year-old man is evaluated in the cardiology clinic 3 days after being discharged from the hospital. He had been admitted for highly symptomatic, recurrent atrial fibrillation, and oral amiodarone was initiated for rhythm control prior to discharge. His medical history is significant for heart failure with reduced ejection fraction and a mechanical aortic valve replacement performed 4 years ago. His home medications include warfarin, digoxin, metoprolol succinate, and lisinopril. On the day of discharge, his international normalized ratio (INR) was 2.8 (target 2.5–3.5) and his serum digoxin level was 0.9 ng/mL (target 0.5–0.9 ng/mL). Today, the patient reports feeling well with no palpitations, visual disturbances, or bleeding. Vital signs are within normal limits. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Cevabı ve açıklamayı göster

Cevap: Decrease the warfarin dose by 30% to 50% and decrease the digoxin dose by 50%

Cevap

Decrease the warfarin dose by 30% to 50% and decrease the digoxin dose by 50%
The correct answer accurately addresses the dual pharmacokinetic interactions caused by amiodarone. Amiodarone inhibits CYP2C9, which decreases the clearance of warfarin, requiring a preemptive 30% to 50% reduction in the weekly warfarin dose to prevent severe bleeding. Simultaneously, amiodarone inhibits P-glycoprotein, which decreases the clearance of digoxin, requiring a preemptive 50% reduction in the digoxin dose to avoid neurotoxicity and fatal arrhythmias. Because both existing drug levels were highly therapeutic on the day of discharge, failing to reduce either dose will predictably lead to toxic accumulation over the next several days.

Adım Adım Çözüm

1
Review the patient's current medication list against the newly initiated drug.
Amiodarone has been added to a regimen that already includes both warfarin and digoxin.
Identifying overlapping pharmacotherapies is essential for anticipating adverse drug reactions.
2
Analyze the specific pharmacokinetic mechanisms of the new medication.
Amiodarone is a potent inhibitor of both the cytochrome P450 2C9 (CYP2C9) enzyme and the P-glycoprotein (P-gp) efflux transporter.
Understanding the precise mechanism dictates the necessary dose adjustments for affected substrates.
3
Determine the required proactive dose adjustments for the affected home medications.
The warfarin dose must be reduced by 30% to 50% to account for CYP2C9 inhibition, and the digoxin dose must be reduced by 50% to account for P-gp inhibition.
Proactive dose reduction prevents supratherapeutic levels, which could lead to life-threatening bleeding and digoxin toxicity.

Anahtar Kavram

Proactive dose adjustments are mandatory when initiating amiodarone in patients taking warfarin (due to CYP2C9 inhibition) and digoxin (due to P-glycoprotein inhibition) to prevent severe toxicity.
Soru 1995Soru →

A 3131-year-old man comes to the clinic for a scheduled follow-up evaluation. Six months ago, he presented with a painless penile ulcer and a diffuse maculopapular rash involving his palms and soles. At that time, a rapid plasma reagin (RPR) test was reactive with a titer of 1:641:64, and a Treponema pallidum particle agglutination (TP-PA) test was positive. He was diagnosed with secondary syphilis and successfully treated with a single intramuscular injection of 2.42.4 million units of benzathine penicillin G. Today, the patient reports feeling well and notes that his rash resolved completely within a few weeks of treatment. He has no new sexual partners and has been consistently using condoms. Vital signs are within normal limits. Physical examination reveals clear skin with no active lesions, rashes, or lymphadenopathy. Neurologic examination shows no abnormalities. Which of the following is the most appropriate next step to evaluate the efficacy of this patient's treatment?

Cevabı ve açıklamayı göster

Cevap: Repeat the rapid plasma reagin test to confirm at least a four-fold reduction in the titer

Cevap

Repeat the rapid plasma reagin test to confirm at least a four-fold reduction in the titer.
The most appropriate next step in evaluating the efficacy of this patient's treatment is to repeat the rapid plasma reagin (RPR) test. Patients who are treated for primary or secondary syphilis must undergo clinical and serologic evaluation at 6 and 12 months following therapy. Treatment success is defined objectively by at least a four-fold decline in the quantitative nontreponemal titer (e.g., a drop from 1:641:64 to 1:161:16 or lower). If the titer fails to decrease appropriately or increases, it suggests either treatment failure or reinfection, prompting consideration for further evaluation (such as cerebrospinal fluid analysis) and re-treatment.

Adım Adım Çözüm

1
Identify the patient's underlying diagnosis and recent intervention.
The patient was diagnosed with secondary syphilis 6 months ago and appropriately treated with intramuscular benzathine penicillin G.
Establishes the timeline and baseline data required to formulate an adequate follow-up and monitoring plan.
2
Determine the standard protocol for post-treatment monitoring of this disease.
Patients treated for primary or secondary syphilis require clinical and serologic evaluation at 6 and 12 months using quantitative nontreponemal tests (RPR or VDRL).
Treponemal tests (TP-PA, FTA-ABS) remain positive for life, whereas nontreponemal titers correlate with disease activity and treatment response.
3
Establish the expected laboratory outcome that indicates successful therapy.
A four-fold or greater decrease in the nontreponemal titer (e.g., from 1:641:64 to 1:161:16 or lower) at 6 to 12 months confirms an adequate response.
This objective metric definitively rules out treatment failure and guides decisions regarding possible re-treatment.

Anahtar Kavram

Post-treatment monitoring of syphilis requires quantitative nontreponemal testing (e.g., RPR) at 6 and 12 months to confirm an adequate serologic response, defined as at least a four-fold decline in titer.
Soru 1996Soru →

A 6464-year-old male is evaluated in the ambulatory clinic for optimization of his medical regimen following a recent discharge for volume overload. An echocardiogram obtained last week demonstrated a left ventricular ejection fraction of 28%28\%. Past medical history is significant for essential hypertension and type 2 diabetes mellitus. He is currently euvolemic, reporting no orthopnea or peripheral edema. His only current medications are oral furosemide and metformin. Vital signs demonstrate a blood pressure of 135/82 mmHg135/82\text{ mmHg} and a heart rate of 76 /min76\text{ /min}. Laboratory studies reveal a serum potassium of 4.2 mEq/L4.2\text{ mEq/L}, a serum creatinine of 1.1 mg/dL1.1\text{ mg/dL}, and a hemoglobin A1c of 8.1%8.1\%. Which of the following medications should be simultaneously initiated to optimize this patient's long-term pharmacotherapy and reduce mortality? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Oral sacubitril-valsartan; Oral metoprolol succinate; Oral dapagliflozin

Cevap

The correct regimen includes oral sacubitril-valsartan, oral metoprolol succinate, and oral dapagliflozin.
The correct combination initiates the pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). In a euvolemic, stable patient with an ejection fraction of 28%, immediate initiation of an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) and an evidence-based beta-blocker (metoprolol succinate, carvedilol, or bisoprolol) is essential to reduce mortality and reverse cardiac remodeling. Furthermore, the addition of an SGLT2 inhibitor like dapagliflozin is indicated for all HFrEF patients regardless of diabetes status, but it provides particularly high utility in this patient by simultaneously addressing his suboptimally controlled type 2 diabetes.

Adım Adım Çözüm

1
Identify the primary clinical condition and patient stability.
The patient has newly diagnosed heart failure with reduced ejection fraction (LVEF 28%) and is currently euvolemic and hemodynamically stable.
Establishing euvolemic status is required before initiating certain beta-blockers, and determining the low LVEF directs the specific classes of medications needed.
2
Determine the necessary foundational guideline-directed medical therapy (GDMT) for the identified condition.
Standard GDMT requires an ARNI (sacubitril-valsartan) or ACEi/ARB, an evidence-based beta-blocker (metoprolol succinate), an MRA, and an SGLT2 inhibitor.
These medication classes have proven mortality and morbidity benefits in patients with reduced ejection fraction.
3
Evaluate the patient's comorbidities and how they intersect with potential pharmacotherapy.
The patient has poorly controlled type 2 diabetes (A1c 8.1%). Dapagliflozin provides dual benefits for both heart failure and diabetes.
Selecting medications with overlapping benefits minimizes polypharmacy and maximizes therapeutic efficacy.
4
Rule out contraindicated medications often used for the patient's comorbidities.
Pioglitazone (for diabetes) and verapamil (for hypertension) must be avoided.
These drugs exacerbate heart failure through fluid retention (pioglitazone) and negative inotropy (verapamil).

Anahtar Kavram

Guideline-directed medical therapy for heart failure with reduced ejection fraction requires multiple simultaneous neurohormonal antagonists, while strictly avoiding contraindicated medications like thiazolidinediones and non-dihydropyridine calcium channel blockers.
Soru 1997Soru →

Match each patient clinical profile with the most appropriate, guideline-concordant preventive care intervention or screening strategy.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

42-year-old woman of Ashkenazi Jewish descent whose paternal grandmother had ovarian cancer
57-year-old asymptomatic man inquiring about routine screening for prostate cancer
28-year-old sexually active man who has sex with men and reports multiple new partners
33-year-old asymptomatic woman who recently immigrated from a tuberculosis-endemic country

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The correct pairings appropriately match each patient's specific risk factors and demographic profile to current USPSTF preventive care guidelines: the Ashkenazi Jewish woman requires a BRCA risk assessment tool, the 57-year-old man requires shared decision-making for PSA screening, the high-risk man requires HIV PrEP evaluation, and the recent immigrant requires latent tuberculosis screening.
Each patient profile correctly maps to an evidence-based guideline tailored to their specific historical and demographic risk factors. The Ashkenazi Jewish patient meets criteria for a familial risk assessment tool due to heightened pre-test probability for BRCA mutations. The 57-year-old man falls into the age bracket (55-69 years) where PSA screening requires individualized shared decision-making. The 28-year-old man's sexual history indicates high risk for HIV, warranting PrEP evaluation. Finally, the 33-year-old woman's recent immigration from an endemic area is a classic trigger for latent tuberculosis screening.

Adım Adım Çözüm

1
Evaluate the 42-year-old woman's oncologic risk profile.
Identify her as high-risk for BRCA1/2 mutations.
Ashkenazi Jewish ancestry combined with a family history of ovarian cancer are established risk factors that necessitate the use of a brief familial risk assessment tool before proceeding to direct genetic testing.
2
Evaluate the 57-year-old man's screening requirements.
Determine the need for a shared decision-making approach.
Current Grade C USPSTF guidelines stipulate that prostate cancer screening in average-risk men aged 55 to 69 should not be routine, but rather based on individualized discussion of potential benefits and harms.
3
Evaluate the 28-year-old man's infectious disease risk profile.
Identify the indication for HIV pre-exposure prophylaxis (PrEP).
Reporting multiple new sexual partners as a man who has sex with men places the patient in a high-risk category, triggering a Grade A recommendation for PrEP evaluation and comprehensive STI screening.
4
Evaluate the 33-year-old woman's epidemiological exposure history.
Select latent tuberculosis screening as the priority intervention.
Recent immigration from a TB-endemic region is a primary indication for latent tuberculosis infection screening using an interferon-gamma release assay or tuberculin skin testing.

Anahtar Kavram

Application of USPSTF and ACIP preventive care and screening guidelines based on patient-specific risk factors, age, and demographic characteristics.
Soru 1998Soru →

A 64-year-old woman is admitted to the hospital with a 3-day history of worsening left lower quadrant abdominal pain, subjective fevers, and nausea. She has a history of diet-controlled type 2 diabetes mellitus and essential hypertension. Her temperature is 38.8∘C38.8^\circ\text{C} (101.8∘F101.8^\circ\text{F}), blood pressure is 118/76 mm Hg118/76\text{ mm Hg}, pulse is 108/min108/\text{min}, and respirations are 18/min18/\text{min}. Physical examination reveals marked tenderness in the left lower quadrant with voluntary guarding. There is no rebound tenderness or abdominal rigidity. Laboratory studies show a leukocyte count of 16,500/mm316,500/\text{mm}^3. Intravenous fluids and broad-spectrum antibiotics are initiated. A computed tomography scan of the abdomen and pelvis with intravenous contrast reveals inflammation of the sigmoid colon with an adjacent 5.5-cm5.5\text{-cm} fluid collection containing gas bubbles and an enhancing rim. Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: CT-guided percutaneous drainage

Cevap

CT-guided percutaneous drainage
Acute diverticulitis complicated by a localized intra-abdominal abscess (Hinchey stage II) requires intervention if the fluid collection is large enough to be accessed safely. Generally, abscesses measuring 3 cm3\text{ cm} or larger are treated with CT-guided percutaneous drainage in addition to intravenous antibiotics. This minimally invasive approach effectively provides source control, resolves sepsis, and avoids the significant morbidity associated with emergent surgical resection (which typically necessitates a colostomy). Following successful drainage and resolution of the acute episode, the patient can be evaluated for an elective, single-stage sigmoid resection.

Adım Adım Çözüm

1
Evaluate the patient's clinical presentation and imaging findings.
The patient has acute complicated diverticulitis with a 5.5-cm5.5\text{-cm} abscess (Hinchey stage II).
Understanding the specific stage and anatomical characteristics of complicated diverticulitis dictates the necessity and type of procedural intervention.
2
Determine the appropriate intervention based on abscess size and patient stability.
Abscesses ≥3 cm\ge 3\text{ cm} are typically amenable to percutaneous drainage.
Minimally invasive drainage achieves source control while avoiding the high morbidity of emergent bowel resection and stoma creation.

Anahtar Kavram

Complicated acute diverticulitis with a localized abscess ≥3 cm\ge 3\text{ cm} (Hinchey stage II) should be managed initially with intravenous antibiotics and CT-guided percutaneous drainage to establish source control without the need for emergent surgery.
Soru 1999Soru →

A 6262-year-old woman is admitted to the hospital with a newly diagnosed acute deep vein thrombosis of the right lower extremity. Her past medical history is significant for active gastric adenocarcinoma and chronic kidney disease stage 4, with a recent baseline creatinine clearance of 24 mL/min24\text{ mL/min}. The clinical team decides to initiate dose-adjusted subcutaneous enoxaparin for therapeutic anticoagulation. Given the patient's comorbidities and pharmacotherapy, which of the following are appropriate monitoring and management strategies? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Measurement of peak anti-factor Xa levels 44 hours after the enoxaparin dose; Regular assessment of platelet count between days 44 and 1414 of therapy

Cevap

The appropriate strategies are measuring peak anti-factor Xa levels 4 hours post-dose and regularly monitoring the platelet count between days 4 and 14.
Enoxaparin is a low-molecular-weight heparin (LMWH) that is primarily cleared by the kidneys. In patients with severe renal impairment (creatinine clearance <30 mL/min< 30\text{ mL/min}), the drug can accumulate and cause severe hemorrhage. Therefore, standard dosing is contraindicated; if used, the dose must be adjusted and closely monitored using peak anti-factor Xa levels drawn 44 hours after the subcutaneous injection. Additionally, any patient receiving a heparin product requires surveillance for heparin-induced thrombocytopenia (HIT). Immune-mediated Type 2 HIT classically occurs 55 to 1010 days after initiation, making routine platelet count checks between days 44 and 1414 a mandatory monitoring parameter.

Adım Adım Çözüm

1
Identify the high-risk pharmacotherapy and relevant patient comorbidities.
The patient is starting enoxaparin (a low-molecular-weight heparin) and has severe chronic kidney disease (creatinine clearance <30 mL/min< 30\text{ mL/min}).
Comorbidities alter the pharmacokinetics and monitoring requirements of anticoagulants.
2
Determine the necessary pharmacokinetic monitoring for the drug in this specific clinical context.
Because enoxaparin is renally cleared, its dose must be reduced in severe renal impairment, and therapeutic efficacy/safety is monitored via peak anti-factor Xa levels drawn 44 hours post-dose.
Standard weight-based dosing without monitoring in severe renal disease leads to drug accumulation and high bleeding risk.
3
Identify class-wide adverse effect monitoring requirements.
All heparin products require monitoring for heparin-induced thrombocytopenia (HIT). The highest risk period for immune-mediated HIT (Type 2) is days 55 to 1010, necessitating platelet count checks between days 44 and 1414.
Type 2 HIT is a limb- and life-threatening prothrombotic complication.

Anahtar Kavram

Patients with severe renal impairment (CrCl <30 mL/min< 30\text{ mL/min}) receiving therapeutic enoxaparin require anti-factor Xa level monitoring. All patients on heparin products require platelet monitoring for HIT.
Soru 2000Soru →

A 71-year-old man comes to his primary care physician for an annual health maintenance examination. His medical history includes hypertension, hyperlipidemia, and osteoarthritis. His current medications are lisinopril, atorvastatin, and acetaminophen as needed. He smoked one pack of cigarettes daily from age 18 until quitting completely at age 48. He drinks one or two alcoholic beverages weekly. The patient received a 20-valent pneumococcal conjugate vaccine at age 66 and completed the 2-dose recombinant zoster vaccine series at age 68. A screening colonoscopy performed at age 63 was entirely normal. He has never undergone any imaging of his chest or abdomen. Vital signs and physical examination today are unremarkable. Which of the following is the most appropriate next step in preventive care for this patient?

Cevabı ve açıklamayı göster

Cevap: One-time ultrasonography of the abdomen

Cevap

One-time ultrasonography of the abdomen
The USPSTF recommends one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked (defined as 100 or more cigarettes in a lifetime). This 71-year-old patient has a substantial smoking history and has never undergone abdominal imaging. Therefore, ordering a one-time ultrasonography of the abdomen is the most appropriate, guideline-concordant next step in his preventive care.

Adım Adım Çözüm

1
Evaluate the patient's demographic risk factors for abdominal aortic aneurysm (AAA).
The patient is a 71-year-old male with a significant smoking history (30 pack-years).
The USPSTF recommends one-time screening for AAA by ultrasonography in men aged 65 to 75 years who have ever smoked (defined as 100 or more cigarettes in a lifetime).
2
Assess eligibility for lung cancer screening.
The patient smoked 1 pack per day for 30 years but quit 23 years ago at age 48.
Annual screening for lung cancer with low-dose computed tomography (LDCT) is indicated for adults aged 50 to 80 years with a 20 pack-year smoking history who currently smoke or have quit within the past 15 years. Because this patient quit more than 15 years ago, he is no longer eligible.
3
Determine current colorectal cancer screening needs.
The patient had a normal screening colonoscopy at age 63.
After a normal screening colonoscopy in an average-risk individual, the recommended interval before the next screening is 10 years. He does not need screening until age 73.
4
Review adult immunization status and prostate cancer screening indications.
The patient is fully vaccinated against pneumococcus (received PCV20) and zoster. He is 71 years old, which places him outside the recommended age for prostate-specific antigen (PSA) screening.
The USPSTF recommends against PSA screening in men aged 70 and older. Furthermore, ACIP guidelines state a single dose of PCV20 is complete coverage for adults aged 65 and older.

Anahtar Kavram

Guideline-concordant preventive care in older adults requires integrating age, smoking history, prior screening results, and updated immunization schedules while actively avoiding outdated tests.
ÖncekiSayfa 100 / 104Sonraki